DEB-BACE + arotinib + tirelizumab

DEB-BACE + arotinib + tirelizumab is an investigational combination therapy comprising three components: - **DEB-BACE** (Drug-Eluting Bead Bronchial Arterial Chemoembolization): A locoregional interventional procedure where chemotherapeutic agents are loaded onto drug-eluting beads and delivered via the bronchial artery to target lung tumors. This approach allows for high local concentrations of chemotherapy with reduced systemic toxicity. - **Arotinib**: A small molecule multi-targeted tyrosine kinase inhibitor that primarily inhibits vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptor (PDGFR), and fibroblast growth factor receptor (FGFR). It is designed to inhibit tumor angiogenesis and cell proliferation. - **Tirelizumab**: A humanized monoclonal antibody targeting programmed death-1 (PD-1) on T cells, functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. This combination is being explored primarily for advanced or refractory non-small cell lung cancer and potentially other solid tumors. The rationale behind this regimen is to combine locoregional cytotoxic therapy with targeted inhibition of angiogenesis and immunotherapy-mediated activation of anti-tumor immunity.

Brand names

Focus VTevimbra

Other names

DEB-BACE + arotinib + tirelizumabanlotinib + tislelizumab + drug-eluting bead bronchial arterial chemoembolizationsequential anlotinib and tislelizumab with DEB-BACE